Adesso, L., Calabretta, S., Barbagallo, F., Capurso, G., Pilozzi, E., Geremia, R., Delle Fave, G., Sette, C., Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene 32 (2013), 2848–2857.
Akman, H.B., Oyken, M., Tuncer, T., Can, T., Erson-Bensan, A.E., 3’UTR shortening and EGF signaling: implications for breast cancer. Hum. Mol. Genet. 24 (2015), 6910–6920.
Albert, B.J., McPherson, P.A., O'Brien, K., Czaicki, N.L., Destefino, V., Osman, S., Li, M., Day, B.W., Grabowski, P.J., Moore, M.J., Vogt, A., Koide, K., Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Mol. Cancer Ther. 8 (2009), 2308–2318.
Albert, H., Battaglia, E., Monteiro, C., Bagrel, D., Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines. Mol. Oncol. 6 (2012), 542–552.
Alló M., Agirre, E., Bessonov, S., Bertucci, P., Gómez Acuña, L., Buggiano, V., Bellora, N., Singh, B., Petrillo, E., Blaustein, M., Miñana, B., Dujardin, G., Pozzi, B., Pelisch, F., Bechara, E., Agafonov, D.E., Srebrow, A., Lührmann, R., Valcárcel, J., Eyras, E., Kornblihtt, A.R., Argonaute-1 binds transcriptional enhancers and controls constitutive and alternative splicing in human cells. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 15622–15629.
Allemand, E., Batsché E., Muchardt, C., Splicing, transcription, and chromatin: a ménage à trois. Curr. Opin. Genet. Dev. 18 (2008), 145–151.
Allende-Vega, N., Dayal, S., Agarwala, U., Sparks, A., Bourdon, J.C., Saville, M.K., p53 is activated in response to disruption of the pre-mRNA splicing machinery. Oncogene 32 (2012), 1–14.
Alsafadi, S., Houy, A., Battistella, A., Popova, T., Wassef, M., Henry, E., Tirode, F., Constantinou, A., Piperno-Neumann, S., Roman-Roman, S., Dutertre, M., Stern, M.H., Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat. Commun., 7, 2016, 10615.
Anderson, E.S., Lin, C.H., Xiao, X., Stoilov, P., Burge, C.B., Black, D.L., The cardiotonic steroid digitoxin regulates alternative splicing through depletion of the splicing factors SRSF3 and TRA2B. RNA 18 (2012), 1041–1049.
Andersson, R., Enroth, S., Rada-Iglesias, A., Wadelius, C., Komorowski, J., Nucleosomes are well positioned in exons and carry characteristic histone modifications. Genome Res. 19 (2009), 1732–1741.
Andreassi, C., Jarecki, J., Zhou, J., Coovert, D.D., Monani, U.R., Chen, X., Whitney, M., Pollok, B., Zhang, M., Androphy, E., Burghes, A.H., Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum. Mol. Genet. 10 (2001), 2841–2849.
Aragaki, M., Takahashi, K., Akiyama, H., Tsuchiya, E., Kondo, S., Nakamura, Y., Daigo, Y., Characterization of a cleavage stimulation factor, 3’ pre-RNA, subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer. Clin. Cancer Res. 17 (2011), 5889–5900.
Aratake, K., Kamachi, M., Iwanaga, N., Kawasaki, E., Izumi, Y., Ida, H., Tanaka, F., Tamai, M., Arima, K., Nakamura, H., Origuchi, T., Kawakami, A., Eguchi, K., A cross-talk between RNA splicing and signaling pathway alters Fas gene expression at post-transcriptional level: alternative splicing of Fas mRNA in the leukemic U937 cells. J. Lab. Clin. Med. 146 (2005), 184–191.
Auboeuf, D., Hönig, A., Berget, S.M., O'Malley, B.W., Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 298 (2002), 416–419.
Auboeuf, D., Batsché E., Dutertre, M., Muchardt, C., O'Malley, B.W., Coregulators: transducing signal from transcription to alternative splicing. Trends Endocrinol. Metab. 18 (2007), 122–129.
Barbier, J., Dutertre, M., Bittencourt, D., Sanchez, G., Gratadou, L., de la Grange, P., Auboeuf, D., Regulation of H-ras splice variant expression by cross talk between the p53 and nonsense-mediated mRNA decay pathways. Mol. Cell Biol. 27 (2007), 7315–7333.
Batsché E., Ameyar-Zazoua, M., The influence of Argonaute proteins on alternative RNA splicing. Wiley Interdiscip. Rev. RNA 6 (2015), 141–156.
Baur, J.A., Sinclair, D.A., Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5 (2006), 493–506.
Bentley, D.L., Coupling mRNA processing with transcription in time and space. Nat. Rev. Genet. 15 (2014), 163–175.
Berg, M.G., Wan, L., Younis, I., Diem, M.D., Soo, M., Wang, C., Dreyfuss, G., A quantitative high-throughput in vitro splicing assay identifies inhibitors of spliceosome catalysis. Mol. Cell. Biol. 32 (2012), 1271–1283.
Boise, L.H., González-García, M., Postema, C.E., Ding, L., Lindsten, T., Turka, L.A., Mao, X., Nuñez, G., Thompson, C.B., bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74 (1993), 597–608.
Busch, A., Hertel, K.J., Evolution of SR protein and hnRNP splicing regulatory factors. Wiley Interdiscip. Rev. RNA 3 (2012), 1–12.
Carroll, B., Donaldson, J.C., Obeid, L., Sphingolipids in the DNA damage response. Adv. Biol. Regul. 58 (2015), 38–52.
Cascino, I., Fiucci, G., Papoff, G., Ruberti, G., Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 154 (1995), 2706–2713.
Chalfant, C.E., Rathman, K., Pinkerman, R.L., Wood, R.E., Obeid, L.M., Ogretmen, B., Hannun, Y.A., De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J. Biol. Chem. 277 (2002), 12587–12595.
Chandler, D.S., Singh, R.K., Caldwell, L.C., Bitler, J.L., Lozano, G., Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res. 66 (2006), 9502–9508.
Chang, J.G., Yang, D.M., Chang, W.H., Chow, L.P., Chan, W.L., Lin, H.H., Huang, H.D., Chang, Y.S., Hung, C.H., Yang, W.K., Small molecule amiloride modulates oncogenic RNA alternative splicing to devitalize human cancer cells. PLoS One, 6, 2011, e18643, 10.1371/journal.pone.0018643.
Chang, W.H., Liu, T.C., Yang, W.K., Lee, C.C., Lin, Y.H., Chen, T.Y., Chang, J.G., Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib. Cancer Res. 71 (2011), 383–392.
Chen, W., Guo, W., Li, M., Shi, D., Tian, Y., Li, Z., Wang, J., Fu, L., Xiao, X., Liu, Q.Q., Wang, S., Huang, W., Deng, W., Upregulation of cleavage and polyadenylation specific factor 4 in lung adenocarcinoma and its critical role for cancer cell survival and proliferation. PLoS One, 8, 2013, e82728, 10.1371/journal.pone.0082728.
Cheng, D., Côté J., Shaaban, S., Bedford, M.T., The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing. Mol. Cell 25 (2007), 71–83.
Chuman, Y., Kurihashi, W., Mizukami, Y., Nashimoto, T., Yagi, H., Sakaguchi, K., PPM1D430, a novel alternative splicing variant of the human PPM1D, can dephosphorylate p53 and exhibits specific tissue expression. J. Biochem. 145 (2009), 1–12.
Cohen-Eliav, M., Golan-Gerstl, R., Siegfried, Z., Andersen, C.L., Thorsen, K., Ørntoft, T.F., Mu, D., Karni, R., The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers. J. Pathol. 229 (2013), 630–639.
Convertini, P., Shen, M., Potter, P.M., Palacios, G., Lagisetti, C., de la Grange, P., Horbinski, C., Fondufe-Mittendorf, Y.N., Webb, T.R., Stamm, S., Sudemycin E influences alternative splicing and changes chromatin modifications. Nucleic Acids Res. 42 (2014), 4947–4961.
Corrionero, A., Miñana, B., Valcárcel, J., Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes Dev. 25 (2011), 445–459.
Cramer, P., Srebrow, A., Kadener, S., Werbajh, S., de la Mata, M., Melen, G., Nogués, G., Kornblihtt, A.R., Coordination between transcription and pre-mRNA processing. FEBS Lett. 498 (2001), 179–182.
Curinha, A., Oliveira Braz, S., Pereira-Castro, I., Cruz, A., Moreira, A., Implications of polyadenylation in health and disease. Nucleus 5 (2014), 508–519.
de Klerk, E., ‘t Hoen, P.A., Alternative mRNA transcription, processing, and translation: insights from RNA sequencing. Trends Genet. 31 (2015), 128–139.
de Klerk, E., Venema, A., Anvar, S.Y., Goeman, J.J., Hu, O., Trollet, C., Dickson, G., den Dunnen, J.T., van der Maarel, S.M., Raz, V., ‘t Hoen, P.A., Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation. Nucleic Acids Res. 40 (2012), 9089–9101.
de la Mata, M., Alonso, C.R., Kadener, S., Fededa, J.P., Blaustein, M., Pelisch, F., Cramer, P., Bentley, D., Kornblihtt, A.R., A slow RNA polymerase II affects alternative splicing in vivo. Mol. Cell 12 (2003), 525–532.
de la Mata, M., Lafaille, C., Kornblihtt, A.R., First come, first served revisited: factors affecting the same alternative splicing event have different effects on the relative rates of intron removal. RNA 16 (2010), 904–912.
Davuluri, R.V., Suzuki, Y., Sugano, S., Plass, C., Huang, T.H., The functional consequences of alternative promoter use in mammalian genomes. Trends Genet. 24 (2008), 167–177.
De Conti, L., Baralle, M., Buratti, E., Exon and intron definition in pre-mRNA splicing. Wiley Interdiscip. Rev. RNA 4 (2013), 49–60.
Di Giammartino, D.C., Nishida, K., Manley, J.L., Mechanisms and consequences of alternative polyadenylation. Mol. Cell 43 (2011), 853–866.
Diederichs, S., Bartsch, L., Berkmann, J.C., Fröse, K., Heitmann, J., Hoppe, C., Iggena, D., Jazmati, D., Karschnia, P., Linsenmeier, M., Maulhardt, T., Möhrmann, L., Morstein, J., Paffenholz, S.V., Röpenack, P., Rückert, T., Sandig, L., Schell, M., Steinmann, A., Voss, G., Wasmuth, J., Weinberger, M.E., Wullenkord, R., The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. EMBO Mol. Med. 8 (2016), 442–457.
Diniz, S.N., Pendeloski, K.P., Morgun, A., Chepelev, I., Gerbase-DeLima, M., Shulzhenko, N., Tissue-specific expression of IL-15RA alternative splicing transcripts and its regulation by DNA methylation. Eur. Cytokine Netw. 21 (2010), 308–318.
Dolnick, B.J., Wu, X.P., Effects of 5-fluorouracil on mRNA. Adv. Exp. Med. Biol. 339 (1993), 57–63.
Dowhan, D.H., Hong, E.P., Auboeuf, D., Dennis, A.P., Wilson, M.M., Berget, S.M., O'Malley, B.W., Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta. Mol. Cell 17 (2005), 429–439.
Dujardin, G., Lafaille, C., de la Mata, M., Marasco, L.E., Muñoz, M.J., Le Jossic-Corcos, C., Corcos, L., Kornblihtt, A.R., How slow RNA polymerase II elongation favors alternative exon skipping. Mol. Cell 54 (2014), 683–690.
Dutertre, M., Sanchez, G., De Cian, M.C., Barbier, J., Dardenne, E., Gratadou, L., Dujardin, G., Le Jossic-Corcos, C., Corcos, L., Auboeuf, D., Cotranscriptional exon skipping in the genotoxic stress response. Nat. Struct. Mol. Biol. 17 (2010), 1358–1366.
Dutertre, M., Chakrama, F.Z., Combe, E., Desmet, F.O., Mortada, H., Polay Espinoza, M., Gratadou, L., Auboeuf, D., A recently evolved class of alternative 3’-terminal exons involved in cell cycle regulation by topoisomerase inhibitors. Nat. Commun., 5, 2014, 3395.
Edmond, V., Moysan, E., Khochbin, S., Matthias, P., Brambilla, C., Brambilla, E., Gazzeri, S., Eymin, B., Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J. 30 (2011), 510–523.
Elkon, R., Ugalde, A.P., Agami, R., Alternative cleavage and polyadenylation: extent: regulation and function. Nat. Rev. Genet. 14 (2013), 496–506.
Eskens, F.A., Ramos, F.J., Burger, H., O'Brien, J.P., Piera, A., de Jonge, M.J., Mizui, Y., Wiemer, E.A., Carreras, M.J., Baselga, J., Tabernero, J., Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin. Cancer Res. 19 (2013), 6296–6304.
Fan, L., Lagisetti, C., Edwards, C.C., Webb, T.R., Potter, P.M., Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem. Biol. 6 (2011), 582–589.
Fidaleo, M., Svetoni, F., Volpe, E., Miñana, B., Caporossi, D., Paronetto, M.P., Genotoxic stress inhibits Ewing sarcoma cell growth by modulating alternative pre-mRNA processing of the RNA helicase DHX9. Oncotarget 6 (2015), 31740–31757.
Filippov, V., Filippova, M., Duerksen-Hughes, P.J., The early response to DNA damage can lead to activation of alternative splicing activity resulting in CD44 splice pattern changes. Cancer Res. 67 (2007), 7621–7630.
Folco, E.G., Coil, K.E., Reed, R., The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes Dev. 25 (2011), 440–444.
Fukuhara, T., Hosoya, T., Shimizu, S., Sumi, K., Oshiro, T., Yoshinaka, Y., Suzuki, M., Yamamoto, N., Herzenberg, L.A., Herzenberg, L.A., Hagiwara, M., Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 11329–11333.
Gabriel, M., Delforge, Y., Deward, A., Habraken, Y., Hennuy, B., Piette, J., Klinck, R., Chabot, B., Colige, A., Lambert, C., Role of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosis. BMC Cancer 15 (2015), 227–240.
Gamazon, E.R., Stranger, B.E., Genomics of alternative splicing: evolution, development and pathophysiology. Hum. Genet. 133 (2014), 679–687.
Ghoshal, K., Jacob, S.T., Ara-ATP impairs 3’-end processing of pre-mRNAs by inhibiting both cleavage and polyadenylation. Nucleic Acids Res. 19 (1991), 5871–5875.
Gout, S., Brambilla, E., Boudria, A., Drissi, R., Lantuejoul, S., Gazzeri, S., Eymin, B., Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma. PLoS One, 7, 2012, e46539, 10.1371/journal.pone.0046539.
Gruber, A.R., Martin, G., Keller, W., Zavolan, M., Means to an end: mechanisms of alternative polyadenylation of messenger RNA precursors. Wiley Interdiscip. Rev. RNA 5 (2014), 183–196.
Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
Hasegawa, M., Miura, T., Kuzuya, K., Inoue, A., Won Ki, S., Horinouchi, S., Yoshida, T., Kunoh, T., Koseki, K., Mino, K., Sasaki, R., Yoshida, M., Mizukami, T., Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product. ACS Chem. Biol. 6 (2011), 229–293.
He, J., Yao, J., Sheng, H., Zhu, J., Involvement of the dual-specificity tyrosine phosphorylation-regulated kinase 1A-alternativesplicing factor-calcium/calmodulin-dependent protein kinase IIδ signaling pathway in myocardial infarction-induced heart failure of rats. J. Card. Fail. 21 (2015), 751–760.
Hong, D.S., Kurzrock, R., Naing, A., Wheler, J.J., Falchook, G.S., Schiffman, J.S., Faulkner, N., Pilat, M.J., O'Brien, J., LoRusso, P., A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA). splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest. New Drugs 32 (2014), 436–444.
Hoskins, A.A., Moore, M.J., The spliceosome: a flexible, reversible macromolecular machine. Trends Biochem. Sci. 37 (2012), 179–188.
Hsin, J.P., Manley, J.L., The RNA polymerase II CTD coordinates transcription and RNA processing. Genes Dev. 26 (2012), 2119–2137.
Hsin, J.P., Xiang, K., Manley, J.L., Function and control of RNA polymerase II C-terminal domain phosphorylation in vertebrate transcription and RNA processing. Mol. Cell Biol. 34 (2014), 2488–2498.
Ip, J.Y., Schmidt, D., Pan, Q., Ramani, A.K., Fraser, A.G., Odom, D.T., Blencowe, B.J., Global impact of RNA polymerase II elongation inhibition on alternative splicing regulation. Genome Res. 21 (2011), 390–401.
Irimia, M., Blencowe, B.J., Alternative splicing: decoding an expansive regulatory layer. Curr. Opin. Cell Biol. 24 (2012), 323–332.
Iwanaga, N., Kamachi, M., Aratake, K., Izumi, Y., Ida, H., Tanaka, F., Tamai, M., Arima, K., Nakamura, H., Origuchi, T., Kawakami, A., Eguchi, K., Regulation of alternative splicing of caspase-2 through an intracellular signaling pathway in response to pro-apoptotic stimuli. J. Lab. Clin. Med. 145 (2005), 105–110.
Jeffries, E.P., Denq, W.H., Bartko, J.C., Trakselis, M.A., Identification, quantification, and evolutionary analysis of a novel isoform of MCM9. Gene 519 (2013), 41–49.
Ji, Z., Luo, W., Li, W., Hoque, M., Pan, Z., Zhao, Y., Tian, B., Transcriptional activity regulates alternative cleavage and polyadenylation. Mol. Syst. Biol., 7, 2011, 534.
Jividen, K., Li, H., Chimeric RNAs generated by intergenic splicing in normal and cancer cells. Genes. Chromosomes Cancer 53 (2014), 963–971.
Kaida, D., Motoyoshi, H., Tashiro, E., Nojima, T., Hagiwara, M., Ishigami, K., Watanabe, H., Kitahara, T., Yoshida, T., Nakajima, H., Tani, T., Horinouchi, S., Yoshida, M., Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat. Chem. Biol. 3 (2007), 576–583.
Kaida, D., The reciprocal regulation between splicing and 3’-end processing. Wiley Interdiscip. Rev. RNA 7 (2016), 499–511.
Kamachi, M., Aramaki, T., Tanimura, S., Ichinose, K., Fujikawa, K., Iwamoto, N., Yoshizaki, A., Ida, H., Kawakami, A., Kohno, M., Eguchi, K., Activation of protein phosphatase causes alternative splicing of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): potential effect on immune surveillance. Biochem. Biophys. Res. Commun. 360 (2007), 280–285.
Kar, S.A., Jankowska, A., Makishima, H., Visconte, V., Jerez, A., Sugimoto, Y., Muramatsu, H., Traina, F., Afable, M., Guinta, K., Tiu, R.V., Przychodzen, B., Sakaguchi, H., Kojima, S., Sekeres, M.A., List, A.F., McDevitt, M.A., Maciejewski, J.P., Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica 98 (2013), 107–113.
Kashyap, M.K., Kumar, D., Villa, R., La Clair, J.J., Benner, C., Sasik, R., Jones, H., Ghia, E.M., Rassenti, L.Z., Kipps, T.J., Burkart, M.D., Castro, J.E., Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B. Haematologica 100 (2015), 945–954.
Kim, H., Choi, K., Kang, H., Lee, S.Y., Chi, S.W., Lee, M.S., Song, J., Im, D., Choi, Y., Cho, S., Identification of a novel function of CX-4945 as a splicing regulator. PLoS One, 9, 2014, e94978, 10.1371/journal.pone.0094978.
Knijnenburg, T.A., Bismeijer, T., Wessels, L.F., Shmulevich, I., A multilevel pan-cancer map links gene mutations to cancer hallmarks. Chin. J. Cancer 34 (2015), 439–449.
Kotake, Y., Sagane, K., Owa, T., Mimori-Kiyosue, Y., Shimizu, H., Uesugi, M., Ishihama, Y., Iwata, M., Mizui, Y., Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat. Chem. Biol. 3 (2007), 570–575.
Krämer, A., The structure and function of proteins involved in mammalian pre-mRNA splicing. Annu. Rev. Biochem. 65 (1996), 367–409.
Kubarek, Ł., Kozłowska, A., Przybylski, M., Lianeri, M., Jagodzinski, P.P., Down-regulation of CXCR4 expression by tamoxifen is associated with DNA methyltransferase 3 B up-regulation in MCF-7 breast cancer cells. Biomed. Pharmacother. 63 (2009), 586–591.
Lagisetti, C., Pourpak, A., Jiang, Q., Cui, X., Goronga, T., Morris, S.W., Webb, T.R., Antitumor compounds based on a natural product consensus pharmacophore. J. Med. Chem. 51 (2008), 6220–6224.
Lagisetti, C., Pourpak, A., Goronga, T., Jiang, Q., Cui, X., Hyle, J., Lahti, J.M., Morris, S.W., Webb, T.R., Synthetic mRNA splicing modulator compounds with in vivo antitumor activity. J. Med. Chem. 52 (2009), 6979–6990.
Landry, J.R., Mager, D.L., Wilhelm, B.T., Complex controls: the role of alternative promoters in mammalian genomes. Trends Genet. 19 (2003), 640–648.
Lents, N.H., Wheeler, L.W., Baldassare, J.J., Dynlacht, B.D., Identification and characterization of a novel Mdm2 splice variant acutely induced by the chemotherapeutic agents adriamycin and actinomycin D. ABBV Cell Cycle 7 (2008), 1580–1586.
Lenzken, S.C., Romeo, V., Zolezzi, F., Cordero, F., Lamorte, G., Bonanno, D., Biancolini, D., Cozzolino, M., Pesaresi, M.G., Maracchioni, A., Sanges, R., Achsel, T., Carrì M.T., Calogero, R.A., Barabino, S.M., Mutant SOD1 and mitochondrial damage alter expression and splicing of genes controlling neuritogenesis in models of neurodegeneration. Hum. Mutat. 32 (2011), 168–182.
Lenzken, S.C., Loffreda, A., Barabino, S.M., RNA splicing: a new player in the DNA damage response. Int. J. Cell Biol., 15363, 2013, 4, 10.1155/2013/153634.
Li, D.K., Tisdale, S., Lotti, F., Pellizzoni, L., SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease. Semin. Cell Dev. Biol. 32 (2014), 22–29.
Li, W., You, B., Hoque, M., Zheng, D., Luo, W., Ji, Z., Park, J.Y., Gunderson, S.I., Kalsotra, A., Manley, J.L., Tian, B., Systematic profiling of poly(A)+ transcripts modulated by core 3’ end processing and splicing factors reveals regulatory rules of alternative cleavage and polyadenylation. PLoS Genet., 11, 2015, e1005166, 10.1371/journal.pgen.1005166.
Licht, K., Jantsch, M.F., Rapid and dynamic transcriptome regulation by RNA editing and RNA modifications. J. Cell Biol. 213 (2016), 15–22.
Liu, J., Lin, J., Huang, L.F., Huang, B., Xu, Y.M., Li, J., Wang, Y., Zhang, J., Yang, W.M., Min, Q.H., Wang, X.Z., Differential expression and alternative splicing of cell cycle genes in imatinib-treated K562 cells. Tumour Biol. 36 (2015), 8127–8136.
Long, J.C., Caceres, J.F., The SR protein family of splicing factors: master regulators of gene expression. Biochem. J. 417 (2009), 15–27.
Luco, R.F., Misteli, T., More than a splicing code: integrating the role of RNA, chromatin and non-coding RNA in alternative splicing regulation. Curr. Opin. Genet. Dev. 21 (2011), 366–372.
Maguire, S.L., Leonidou, A., Wai, P., Marchiò C., Ng, C.K., Sapino, A., Salomon, A.V., Reis-Filho, J.S., Weigelt, B., Natrajan, R.C., SF3B1 mutations constitute a novel therapeutic target in breast cancer. J. Pathol. 235 (2015), 571–580.
Makishima, H., Visconte, V., Sakaguchi, H., Jankowska, A.M., Abu Kar, S., Jerez, A., Przychodzen, B., Bupathi, M., Guinta, K., Afable, M.G., Sekeres, M.A., Padgett, R.A., Tiu, R.V., Maciejewski, J.P., Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 119 (2012), 3203–3210.
Mandel, C.R., Bai, Y., Tong, L., Protein factors in pre-mRNA 3’-end processing. Cell Mol. Life Sci. 65 (2008), 1099–1122.
Maniatis, T., Reed, R., An extensive network of coupling among gene expression machines. Nature 416 (2002), 499–506.
Manley, J.L., Tacke, R., SR proteins and splicing control. Genes Dev. 10 (1996), 1569–1579.
Markey, M., Berberich, S.J., Full-length hdmX transcripts decrease following genotoxic stress. Oncogene 27 (2008), 6657–6666.
Markus, M.A., Marques, F.Z., Morris, B.J., Resveratrol, by modulating RNA processing factor levels, can influence the alternative splicing of pre-mRNAs. PLoS One, 6, 2011, e28926, 10.1371/journal.pone.0028926.
Martinez, E., Palhan, V.B., Tjernberg, A., Lymar, E.S., Gamper, A.M., Kundu, T.K., Chait, B.T., Roeder, R.G., Human STAGA complex is a chromatin-acetylating transcription coactivator that interacts with pre-mRNA splicing and DNA damage-binding factors in vivo. Mol. Cell Biol. 21 (2001), 6782–6795.
Matera, A.G., Wang, Z., A day in the life of the spliceosome. Nat. Rev. Mol. Cell Biol. 15 (2014), 108–121.
McGlincy, N.J., Smith, C.W., Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense?. Trends Biochem. Sci. 33 (2008), 385–393.
Merdzhanova, G., Edmond, V., De Seranno, S., Van den Broeck, A., Corcos, L., Brambilla, C., Brambilla, E., Gazzeri, S., Eymin, B., E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35. Cell Death Differ. 15 (2008), 1815–1823.
Mermoud, J.E., Cohen, P., Lamond, A.I., Ser/Thr-specific protein phosphatases are required for both catalytic steps of pre-mRNA splicing. Nucleic Acids Res. 20 (1992), 5263–5269.
Million, K., Horvilleur, E., Goldschneider, D., Agina, M., Raguénez, G., Tournier, F., Bénard, J., Douc-Rasy, S., Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells. Int. J. Oncol. 29 (2006), 147–154.
Mineur, P., Colige, A.C., Deroanne, C.F., Dubail, J., Kesteloot, F., Habraken, Y., Noël, A., Vöö S., Waltenberger, J., Lapière, C.M., Nusgens, B.V., Lambert, C.A., Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents. J. Cell Biol. 179 (2007), 1261–1273.
Mitsui, T., Koiso, H., Nakahashi, H., Saitoh, A., Shimizu, H., Ishizak, i., Ogawa, T., Takizawa, Y., Yokohama, M., Saitoh, A., Jinbo, T., Ogura, T., Handa, H., Sawamura, H., Sakura, M., Karasawa, T., Murakami, M., Nojima, H., Tsukamoto, Y., SF3B1 and IGHV gene mutation status predict poor prognosis in Japanese CLL patients. Int. J. Hematol. 103 (2016), 219–226.
Mizui, Y., Sakai, T., Iwata, M., Uenaka, T., Okamoto, K., Shimizu, H., Yamori, T., Yoshimatsu, K., Asada, M., Pladienolides, new substances from culture of Streptomyces platensis Mer-11107: III. In vitro and in vivo antitumor activities. J. Antibiot. (Tokyo) 57 (2004), 188–196.
Muñoz, M.J., de la Mata, M., Kornblihtt, A.R., The carboxy terminal domain of RNA polymerase II and alternative splicing. Trends Biochem. Sci. 35 (2010), 497–504.
Munaut, C., Colige, A.C., Lambert, C.A., Alternative splicing: a promising target for pharmaceutical inhibition of pathological angiogenesis?. Curr. Pharm. Des. 16 (2010), 3864–3876.
Muraki, M., Ohkawara, B., Hosoya, T., Onogi, H., Koizumi, J., Koizumi, T., Sumi, K., Yomoda, J., Murray, M.V., Kimura, H., Furuichi, K., Shibuya, H., Krainer, A.R., Suzuki, M., Hagiwara, M., Manipulation of alternative splicing by a newly developed inhibitor of Clks. J. Biol. Chem. 279 (2004), 24246–24254.
Neutelings, T., Lambert, C.A., Nusgens, B.V., Colige, A.C., Effects of mild cold shock (25 °C) followed by warming up at 37 °C on the cellular stress response. PLoS One, 8, 2013, e69687, 10.1371/journal.pone.0069687.
Ni, T., Yang, Y., Hafez, D., Yang, W., Kiesewetter, K., Wakabayashi, Y., Ohler, U., Peng, W., Zhu, J., Distinct polyadenylation landscapes of diverse human tissues revealed by a modified PA-seq strategy. BMC Genomics 14 (2013), 615–629.
Nishida, A., Kataoka, N., Takeshima, Y., Yagi, M., Awano, H., Ota, M., Itoh, K., Hagiwara, M., Matsuo, M., Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat. Commun. 2 (2011), 308–315.
Nogués, G., Kadener, S., Cramer, P., Bentley, D., Kornblihtt, A.R., Transcriptional activators differ in their abilities to control alternative splicing. J. Biol. Chem. 277 (2002), 43110–43114.
Nogués, G., Kadener, S., Cramer, P., de la Mata, M., Fededa, J.P., Blaustein, M., Srebrow, A., Kornblihtt, A.R., Control of alternative pre-mRNA splicing by RNA Pol II elongation: faster is not always better. IUBMB Life 55 (2003), 235–241.
O'Brien, K., Matlin, A.J., Lowell, A.M., Moore, M.J., The biflavonoid isoginkgetin is a general inhibitor of Pre-mRNA splicing. J. Biol. Chem. 283 (2008), 33147–33154.
Ohkura, N., Takahashi, M., Yaguchi, H., Nagamura, Y., Tsukada, T., Coactivator-associated arginine methyltransferase 1, CARM1, affects pre-mRNA splicing in an isoform-specific manner. J. Biol. Chem. 280 (2005), 28927–28935.
Pal, S., Gupta, R., Davuluri, R.V., Alternative transcription and alternative splicing in cancer. Pharmacol. Ther. 136 (2012), 283–294.
Park, J.Y., Li, W., Zheng, D., Zhai, P., Zhao, Y., Matsuda, T., Vatner, S.F., Sadoshima, J., Tian, B., Comparative analysis of mRNA isoform expression in cardiac hypertrophy and development reveals multiple post-transcriptional regulatory modules. PLoS One, 6, 2011, e22391, 10.1371/journal.pone.0022391.
Pawellek, A., McElroy, S., Samatov, T., Mitchell, L., Woodland, A., Ryder, U., Gray, D., Lührmann, R., Lamond, A.I., Identification of small molecule inhibitors of pre-mRNA splicing. J. Biol. Chem. 289 (2014), 34683–34698.
Peterson, M.L., Mechanisms controlling production of membrane and secreted immunoglobulin during B cell development. Immunol. Res. 37 (2007), 33–46.
Pham, D., Koide, K., Discoveries, target identifications, and biological applications of natural products that inhibit splicing factor 3B subunit 1. Nat. Prod. Rep. 33 (2016), 637–647.
Phelps, D.E., Hsiao, K.M., Li, Y., Hu, N., Franklin, D.S., Westphal, E., Lee, E.Y., Xiong, Y., Coupled transcriptional and translational control of cyclin-dependent kinase inhibitor p18INK4c expression during myogenesis. Mol. Cell. Biol. 18 (1998), 2334–2343.
Pilch, B., Allemand, E., Facompré M., Bailly, C., Riou, J.F., Soret, J., Tazi, J., Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res. 61 (2001), 6876–6884.
Pinto, P.A., Henriques, T., Freitas, M.O., Martins, T., Domingues, R.G., Wyrzykowska, P.S., Coelho, P.A., Carmo, A.M., Sunkel, C.E., Proudfoot, N.J., Moreira, A., RNA polymerase II kinetics in polo polyadenylation signal selection. EMBO J. 30 (2011), 2431–2444.
Proudfoot, N.J., Furger, A., Dye, M.J., Integrating mRNA processing with transcription. Cell 108 (2002), 501–512.
Quelle, D.E., Zindy, F., Ashmun, R.A., Sherr, C.J., Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83 (1995), 993–1000.
Quesada, V., Conde, L., Villamor, N., Ordóñez, G.R., Jares, P., Bassaganyas, L., Ramsay, A.J., Beà S., Pinyol, M., Martínez-Trillos, A., López-Guerra, M., Colomer, D., Navarro, A., Baumann, T., Aymerich, M., Rozman, M., Delgado, J., Giné E., Hernández, J.M., González-Díaz, M., Puente, D.A., Velasco, G., Freije, J.M., Tubío, J.M., Royo, R., Gelpí J.L., Orozco, M., Pisano, D.G., Zamora, J., Vázquez, M., Valencia, A., Himmelbauer, H., Bayés, M., Heath, S., Gut, M., Gut, I., Estivill, X., López-Guillermo, A., Puente, X.S., Campo, E., López-Otín, C., Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44 (2011), 47–52.
Rahmutulla, B., Matsushita, K., Satoh, M., Seimiya, M., Tsuchida, S., Kubo, S., Shimada, H., Ohtsuka, M., Miyazaki, M., Nomura, F., Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway. Oncotarget 5 (2014), 2404–2417.
Renshaw, J., Orr, R.M., Walton, M.I., Te Poele, R., Williams, R.D., Wancewicz, E.V., Monia, B.P., Workman, P., Pritchard-Jones, K., Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival. Mol. Cancer Ther. 3 (2004), 1467–1484.
Rino, J., Carmo-Fonseca, M., The spliceosome: a self-organized macromolecular machine in the nucleus?. Trends Cell Biol. 19 (2009), 375–384.
Robertson, K.D., Jones, P.A., Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene 18 (1999), 3810–3820.
Rossi, D., Bruscaggin, A., Spina, V., Rasi, S., Khiabanian, H., Messina, M., Fangazio, M., Vaisitti, T., Monti, S., Chiaretti, S., Guarini, A., Del Giudice, I., Cerri, M., Cresta, S., Deambrogi, C., Gargiulo, E., Gattei, V., Forconi, F., Bertoni, F., Deaglio, S., Rabadan, R., Pasqualucci, L., Foà R., Dalla-Favera, R., Gaidano, G., Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 118 (2011), 6904–6908.
Sakashita, E., Endo, H., SR and SR-related proteins redistribute to segregated fibrillar components of nucleoli in a response to DNA damage. Nucleus 1 (2010), 367–380.
Sakla, M.S., Lorson, C.L., Induction of full-length survival motor neuron by polyphenol botanical compounds. Hum. Genet. 122 (2008), 635–643.
Salton, M., Misteli, T., Small molecule modulators of pre-mRNA splicing in cancer therapy. Trends Mol. Med. 22 (2016), 28–37.
Schwartz, S., Meshorer, E., Ast, G., Chromatin organization marks exon-intron structure. Nat. Struct. Mol. Biol. 16 (2009), 990–995.
Shepard, P.J., Choi, E.A., Lu, J., Flanagan, L.A., Hertel, K.J., Shi, Y., Complex and dynamic landscape of RNA polyadenylation revealed by PAS-Seq. RNA 17 (2011), 761–772.
Shilo, A., Siegfried, Z., Karni, R., The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression. Mol. Cell. Oncol., 2, 2015, e970955, 10.4161/23723548.2014.970955.
Shkreta, L., Chabot, B., The RNA splicing response to DNA damage. Biomolecules 5 (2015), 2935–2977.
Shkreta, L., Froehlich, U., Paquet, E.R., Toutant, J., Elela, S.A., Chabot, B., Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes. Mol. Cancer Ther. 7 (2008), 1398–1409.
Shkreta, L., Michelle, L., Toutant, J., Tremblay, M.L., Chabot, B., The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x. J. Biol. Chem. 286 (2011), 331–340.
Shultz, J.C., Goehe, R.W., Wijesinghe, D.S., Murudkar, C., Hawkins, A.J., Shay, J.W., Minna, J.D., Chalfant, C.E., Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res. 70 (2010), 9185–9196.
Singh, R.K., Cooper, T.A., Pre-mRNA splicing in disease and therapeutics. Trends Mol. Med. 18 (2012), 472–482.
Siqueira, R.P., de A. Barbosa, É., Polêto, M.D., Righetto, G.L., Seraphim, T.V., Salgado, R.L., Ferreira, J.G., Barros, M.V., de Oliveira, L.L., Laranjeira, A.B., Almeida, M.R., Júnior, A.S., Fietto, J.L., Kobarg, J., de Oliveira, E.B., Teixeira, R.R., Borges, J.C., Yunes, J.A., Bressan, G.C., Potential antileukemia effect and structural analyses of SRPK inhibition by N-(2-(piperidin-1-yl)-5-(trifluoromethyl.phenyl)isonicotinamide (SRPIN340). PLoS One, 10, 2015, e0134882, 10.1371/journal.pone.0134882.
Solier, S., Lansiaux, A., Logette, E., Wu, J., Soret, J., Tazi, J., Bailly, C., Desoche, L., Solary, E., Corcos, L., Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol. Cancer Res. 2 (2004), 53–61.
Solier, S., Logette, E., Desoche, L., Solary, E., Corcos, L., Nonsense-mediated mRNA decay among human caspases: the caspase-2S putative protein is encoded by an extremely short-lived mRNA. Cell Death Differ. 12 (2005), 687–689.
Solier, S., Barb, J., Zeeberg, B.R., Varma, S., Ryan, M.C., Kohn, K.W., Weinstein, J.N., Munson, P.J., Pommier, Y., Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors. Cancer Res. 70 (2010), 8055–8065.
Spiropoulou, T., Ferekidou, L., Angelopoulou, K., Stathopoulou, A., Talieri, M., Lianidou, E.S., Effect of antineoplastic agents on the expression of human telomerase reverse transcriptase beta plus transcript in MCF-7 cells. Clin. Biochem. 37 (2004), 299–304.
Spraggon, L., Cartegni, L., U1 snRNP-dependent suppression of polyadenylation: physiological role and therapeutic opportunities in cancer. Int. J. Cell Biol., 2013, 846510, 10.1155/2013/846510.
Sun, Y., Fu, Y., Li, Y., Xu, A., Genome-wide alternative polyadenylation in animals: insights from high-throughput technologies. J. Mol. Cell Biol. 4 (2012), 352–361.
Tazi, J., Rossi, F., Labourier, E., Gallouzi, I., Brunel, C., Antoine, E., DNA topoisomerase I: customs officer at the border between DNA and RNA worlds?. J. Mol. Med. 75 (1997), 786–800.
Tazi, J., Bakkour, N., Soret, J., Zekri, L., Hazra, B., Laine, W., Baldeyrou, B., Lansiaux, A., Bailly, C., Selective inhibition of topoisomerase I and various steps of spliceosome assembly by diospyrin derivatives. Mol. Pharmacol. 67 (2005), 1186–1194.
Terns, M.P., Jacob, S.T., Role of poly(A) polymerase in the cleavage and polyadenylation of mRNA precursor. Mol. Cell Biol. 9 (1989), 1435–1444.
Thuresson, A.C., Kirsebom, L.A., Virtanen, A., Inhibition of poly(A) polymerase by aminoglycosides. Biochimie 89 (2007), 1221–1227.
Tian, B., Manley, J.L., Alternative cleavage and polyadenylation: the long and short of it. Trends Biochem. Sci. 38 (2013), 312–320.
Tilgner, H., Nikolaou, C., Althammer, S., Sammeth, M., Beato, M., Valcárcel, J., Guigó R., Nucleosome positioning as a determinant of exon recognition. Nat. Struct. Mol. Biol. 16 (2009), 996–1001.
Tolstrup, A.B., Bejder, A., Fleckner, J., Justesen, J., Transcriptional regulation of the interferon-gamma-inducible tryptophanyl-tRNA synthetase includes alternative splicing. J. Biol. Chem. 270 (1995), 397–403.
Velasco-Miguel, S., Buckbinder, L., Jean, P., Gelbert, L., Talbott, R., Laidlaw, J., Seizinger, B., Kley, N., PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. Oncogene 18 (1999), 127–137.
Venables, J.P., Klinck, R., Koh, C., Gervais-Bird, J., Bramard, A., Inkel, L., Durand, M., Couture, S., Froehlich, U., Lapointe, E., Lucier, J.F., Thibault, P., Rancourt, C., Tremblay, K., Prinos, P., Chabot, B., Elela, S.A., Cancer-associated regulation of alternative splicing. Nat. Struct. Mol. Biol. 16 (2009), 670–676.
Verhaart, I.E., Aartsma-Rus, A., The effect of 6-thioguanine on alternative splicing and antisense-mediated exon skipping treatment for duchenne muscular dystrophy. PLoS Curr. 4:December (12) (2012), 1–15, 10.1371/currents.md.597d700f92eaa70de261ea0d91821377 pii: ecurrents.md.597d700f92eaa70de261ea0d91821377.
Villa, R., Kashyap, M.K., Kumar, D., Kipps, T.J., Castro, J.E., La Clair, J.J., Burkart, M.D., Stabilized cyclopropane analogs of the splicing inhibitor FD-895. J. Med. Chem. 56 (2013), 6576–6582.
Visconte, V., Makishima, H., Jankowska, A., Szpurka, H., Traina, F., Jerez, A., O'Keefe, C., Rogers, H.J., Sekeres, M.A., Maciejewski, J.P., Tiu, R.V., SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 26 (2012), 542–545.
Vivarelli, S., Lenzken, S.C., Ruepp, M.D., Ranzini, F., Maffioletti, A., Alvarez, R., Mühlemann, O., Barabino, S.M., Paraquat modulates alternative pre-mRNA splicing by modifying the intracellular distribution of SRPK2. PLoS One, 8, 2013, e61980, 10.1371/journal.pone.0061980.
Vlasova-St Louis, I., Bohjanen, P.R., Coordinate regulation of mRNA decay networks by GU-rich elements and CELF1. Curr. Opin. Genet. Dev. 21 (2011), 444–451.
Wahl, M.C., Will, C.L., Lührmann, R., The spliceosome: design principles of a dynamic RNP machine. Cell 136 (2009), 701–718.
Wakasugi, K., Slike, B.M., Hood, J., Otani, A., Ewalt, K.L., Friedlander, M., Cheresh, D.A., Schimmel, P., A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 173–177.
Wang, G.S., Cooper, T.A., Splicing in disease: disruption of the splicing code and the decoding machinery. Nat. Rev. Genet. 8 (2007), 749–761.
White, E.J., Brewer, G., Wilson, G.M., Post-transcriptional control of gene expression by AUF1: mechanisms, physiological targets, and regulation. Biochim. Biophys. Acta 1829 (2013), 680–688.
Will, C.L., Lührmann, R., Spliceosome structure and function. Cold Spring Harb. Perspect. Biol., 3, 2011, 10.1101/cshperspect.a003707 (pii: a003707).
Wirth, B., Brichta, L., Hahnen, E., Spinal muscular atrophy: from gene to therapy. Semin. Pediatr. Neurol. 13 (2006), 121–131.
Wotawa, A., Solier, S., Logette, E., Solary, E., Corcos, L., Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells. Cancer Lett. 185 (2002), 181–189.
Wu, W., Yan, C., Gan, T., Chen, Z., Lu, X., Duerksen-Hughes, P.J., Zhu, X., Yang, J., Nuclear proteome analysis of cisplatin-treated HeLa cells. Mutat. Res. 691 (2010), 1–8.
Xargay-Torrent, S., López-Guerra, M., Rosich, L., Montraveta, A., Roldán, J., Rodríguez, V., Villamor, N., Aymerich, M., Lagisetti, C., Webb, T.R., López-Otín, C., Campo, E., Colomer, D., The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. Oncotarget 6 (2015), 22734–22749.
Yokoi, A., Kotake, Y., Takahashi, K., Kadowaki, T., Matsumoto, Y., Minoshima, Y., Sugi, N.H., Sagane, K., Hamaguchi, M., Iwata, M., Mizui, Y., Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J. 278 (2011), 4870–4880.
Yomoda, J., Muraki, M., Kataoka, N., Hosoya, T., Suzuki, M., Hagiwara, M., Kimura, H., Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A. Genes Cells 13 (2008), 233–244.
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., Chalkidis, G., Suzuki, Y., Shiosaka, M., Kawahata, R., Yamaguchi, T., Otsu, M., Obara, N., Sakata-Yanagimoto, M., Ishiyama, K., Mori, H., Nolte, F., Hofmann, W.K., Miyawaki, S., Sugano, S., Haferlach, C., Koeffler, H.P., Shih, L.Y., Haferlach, T., Chiba, S., Nakauchi, H., Miyano, S., Ogawa, S., Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478 (2011), 64–69.
Younis, I., Berg, M., Kaida, D., Dittmar, K., Wang, C., Dreyfuss, G., Rapid-response splicing reporter screens identify differential regulators of constitutive and alternative splicing. Mol. Cell. Biol. 30 (2010), 1718–1728.
Zaharieva, E., Chipman, J.K., Soller, M., Alternative splicing interference by xenobiotics. Toxicology 296 (2012), 1–12.
Zhang, Z., Kelemen, O., van Santen, M.A., Yelton, S.M., Wendlandt, A.E., Sviripa, V.M., Bollen, M., Beullens, M., Urlaub, H., Lührmann, R., Watt, D.S., Stamm, S., Synthesis and characterization of pseudocantharidins, novel phosphatase modulators that promote the inclusion of exon 7 into the SMN (survival of motoneuron) pre-mRNA. J. Biol. Chem. 286 (2011), 10126–10136.
Zhou, Z., Qiu, J., Liu, W., Zhou, Y., Plocinik, R.M., Li, H., Hu, Q., Ghosh, G., Adams, J.A., Rosenfeld, M.G., Fu, X.D., The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol. Cell 47 (2012), 422–433.
Zhu, N., Gu, L., Findley, H.W., Li, F., Zhou, M., An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 23 (2004), 7545–7551.
